Hypoxia-induced LINC00674 facilitates hepatocellular carcinoma progression by activating the NOX1/mTOR signaling pathway

被引:6
|
作者
Zhu, Ning [1 ]
Chen, Xiaohong [2 ]
Zhao, Junjun [1 ,3 ]
Fang, Lijuan [4 ]
Yao, Yingmin [5 ]
Zhou, Feifei [6 ]
Tao, Liang [7 ]
Xu, Qiuran [1 ]
机构
[1] Hangzhou Med Coll, Affiliated Peoples Hosp, Zhejiang Prov Peoples Hosp, Key Lab Tumor Mol Diag & Individualized Med Zheji, Hangzhou 310014, Peoples R China
[2] Haining Hosp, Dept Pediat, Cent Hosp Haining, Zhejiang Prov Peoples Hosp, Haining 314400, Peoples R China
[3] Bengbu Med Coll, Grad Dept, Bengbu 233030, Peoples R China
[4] Hangzhou Ninth Peoples Hosp, Dept Lab, Hangzhou 310014, Peoples R China
[5] Xi An Jiao Tong Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Xian 710061, Peoples R China
[6] Hangzhou Med Coll, Affiliated Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Tradit Chinese Med, Hangzhou 310014, Peoples R China
[7] Haining Hosp, Dept Gen Surg, Cent Hosp Haining, Zhejiang Prov Peoples Hosp, Haining 3144111, Peoples R China
来源
JOURNAL OF CANCER | 2022年 / 13卷 / 11期
基金
中国博士后科学基金;
关键词
Hepatocellular carcinoma; Hypoxia; LINC00674; NOX1; mTOR pathway; PROMOTES; METASTASIS; EXPRESSION; INVASION; ROLES; CELLS;
D O I
10.7150/jca.76458
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The hypoxic tumor microenvironment, a fundamental feature of solid tumors, drives hepatocellular carcinoma (HCC) progression through regulating the transcriptional activities of protein-coding and noncoding genes. However, long noncoding RNA (lncRNA)-mediated HCC progression in hypoxic microenvironment remains largely unknown yet. In this study, we found that LINC00674 was upregulated under hypoxic conditions in a HIF-1-dependent manner, and the occupancy of HIF-1 to HRE of LINC00674 gene promoter was essential for its transcription. In addition, LINC00674 level was increased in HCC cell lines and tissues. Clinically, statistical analysis showed that LINC00674 expression was significantly associated with tumor size, venous infiltration, tumor stage and poor prognosis of HCC. Functionally, loss-of-function assays revealed that LINC00674 knockdown inhibited the migration, proliferation and invasion of HCC cells. Furthermore, LINC00674 silencing prominently repressed the mTOR signaling pathway. LINC00674 overexpression-enhanced HCC cell proliferation, migration and invasion were markedly abolished by an mTOR inhibitor rapamycin. NADPH oxidase 1 (NOX1) was positively regulated by LINC00674 in HCC cells. NOX1 knockdown markedly reversed LINC00674-upregulated the p-mTOR level and HCC cells' malignant behaviors. Finally, we found that LINC00674 knockdown attenuated the growth of HCC cells in vivo. Our finding demonstrated that LINC00674 was a new HIF-1 target gene, and hypoxia-induced LINC00674 exerted a pro-proliferative and pro-metastatic role in HCC, possibly by activating the NOX1/mTOR signaling pathway. This study suggested LINC00674 as a promising therapeutic target for HCC.
引用
收藏
页码:3177 / 3188
页数:12
相关论文
共 50 条
  • [31] LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma
    Teng, Fei
    Zhang, Ju-Xiang
    Chang, Qi-Meng
    Wu, Xu-Bo
    Tang, Wei-Guo
    Wang, Jian-Fa
    Feng, Jin-Feng
    Zhang, Zi-Ping
    Hu, Zhi-Qiu
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [32] RETRACTED: Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway (Retracted Article)
    Malale, Kija
    Fu, Jili
    Qiu, Liewang
    Zhan, Ke
    Gan, Xiuni
    Mei, Zhechuan
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4321 - 4333
  • [33] PLAUR facilitates the progression of clear cell renal cell carcinoma by activating the PI3K/AKT/mTOR signaling pathway
    Qin, Tianzi
    Huang, Minyu
    Wei, Wenjuan
    Zhou, Wei
    Tang, Qianli
    Huang, Qun
    Tang, Ning
    Gai, Shasha
    PEERJ, 2024, 12
  • [34] LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling
    Liu, Ji
    Xu, Rui
    Mai, Shi-Juan
    Ma, Yu-Shui
    Zhang, Mei-Yin
    Cao, Ping-Sheng
    Weng, Nuo-Qing
    Wang, Rui-Qi
    Cao, Di
    Wei, Wei
    Guo, Rong-Ping
    Zhang, Yao-Jun
    Xu, Li
    Chen, Min-Shan
    Zhang, Hui-Zhong
    Huang, Long
    Fu, Da
    Wang, Hui-Yun
    THERANOSTICS, 2020, 10 (17): : 7527 - 7544
  • [35] Hypoxia-induced regulation of mTOR signaling by miR-7 targeting REDD1
    Seong, Minhyeong
    Lee, Jihui
    Kang, Hara
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (03) : 4523 - 4532
  • [36] VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway
    Pu, Zhangya
    Duda, Dan G.
    Zhu, Yuanyuan
    Pei, Siya
    Wang, Xiaofang
    Huang, Yan
    Yi, Panpan
    Huang, Zebing
    Peng, Fang
    Hu, Xingwang
    Fan, Xuegong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [37] ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling
    Xie, Binhui
    Zen, Qinshan
    Wang, Xiaonong
    He, Xiao
    Xie, Yuankang
    Zhang, Zixiang
    Li, Heping
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (05) : 2057 - 2066
  • [38] PCK1 attenuates tumor stemness via activating the Hippo signaling pathway in hepatocellular carcinoma
    Liu, Rui
    Liu, Yi
    Zhang, Wenlu
    Zhang, Guiji
    Zhang, Zhirong
    Huang, Luyi
    Tang, Ni
    Wang, Kai
    GENES & DISEASES, 2024, 11 (04)
  • [39] Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT/mTOR pathway
    Wang, Chengmeng
    Zhang, Lu
    Cao, Manqing
    Fu, Zhou
    Wang, Huaqi
    Zhang, Su
    Zhu, Keyun
    Hou, Zhenyu
    Cui, Jinfang
    Yue, Ping
    Guo, Hua
    Zhang, Ti
    FASEB JOURNAL, 2023, 37 (06)
  • [40] CTHRC1 overexpression promotes cervical carcinoma progression by activating the Wnt/PCP signaling pathway
    Zheng, Mei
    Zhou, Qin
    Liu, Xingguang
    Wang, Chengze
    Liu, Gangli
    ONCOLOGY REPORTS, 2019, 41 (03) : 1531 - 1538